Anaplastic Large Cell Lymphoma, ALK-Positive

Anaplastic Large Cell Lymphoma, ALK-Positive — Trials · CancerIndex

Clinical trials

Registered studies

20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 6
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: Baylor College of Medicine
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–20 of 20 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03113500	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma	active not recruiting	Phase 2	48	City of Hope Medical CenterOTHER	2	Aug 21, 2026	clinicaltrials
NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	active not recruiting	Phase 2	68	National Cancer Institute (NCI)NIH	1	Aug 13, 2026